Publications - Page 27 sur 57 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Hypertension pulmonaire (HTP)
Long-term Outcome of Children with Newly Diagnosed Pulmonary Arterial Hypertension: Results From the Global TOPP-registry.

Ploegstra MJ, Dunbar Ivy D, Beghetti M, Bonnet D, Alehan D, Ablonczy L, Mattos S, Bowers D, Humpl T, Berger RMF; TOPP Investigators.

Eur Heart J Qual Care Clin Outcomes. 2023 Mar 27:qcad020.
Hypertension pulmonaire (HTP)
Changes in the management of chronic thromboembolic pulmonary hypertension over a 10-year period, in a French expert regional competence centre.

Provost M, Mornex JF, Nasser M, Zeghmar S, Traclet J, Ahmad K, Lestelle F, Chour A, Diesler R, Cottin V, Turquier S.

Respir Med Res. 2023 Jun 3;84:101021.
Hypertension pulmonaire (HTP)
Do Low-Risk Pulmonary Arterial Hypertension Patients Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial.

Fauvel C, Liu Y, Correa-Jaque P, Kanwar MK, Vizza CD, Lin S, Benza RL.

Chest. 2023 Jun 24:S0012-3692(23)00925-X.
Hypertension pulmonaire (HTP)
Patients’ perceptions on clinical trials outcomes in pulmonary arterial hypertension therapy.

Mai V, Gosselin C, Tremblay É, Rompré G, Lajoie AC, Weatherald J, Lega JC, Bonnet S, Provencher S.

Thorax. 2023 Jul;78(7):721-725.
Hypertension pulmonaire (HTP)
The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohort.

Colalillo A, Hoffmann-Vold AM, Pellicano C, Romaniello A, Gabrielli A, Hachulla E, Smith V, Simeón-Aznar CP, Castellví I, Airò P, Truchetet ME, Siegert E, Distler O, Rosato E; EUSTAR collaborators.

Autoimmun Rev. 2023 Apr;22(4):103290.
Hypertension pulmonaire (HTP)
Hemodynamic characteristics in patients with pulmonary hypertension and chronic obstructive pulmonary disease: A retrospective monocentric cohort study.

Thoré P, Staentzel J, Valentin S, Guillaumot A, Selton-Suty C, Gomez E, Chabot F, Chaouat A.

Respir Med Res. 2023 Jun;83:101008.
Hypertension pulmonaire (HTP)
AMPK activation by metformin protects against pulmonary hypertension in rats and relaxes isolated human pulmonary artery.

Abdelazeem H, Tu L, Thuillet R, Ottaviani M, Boulfrad A, Beck T, Senbel A, Mani S, Castier Y, Guyard A, Tran-Dinh A, El-Benna J, Longrois D, Silverstein AM, Guignabert C, Norel X.

ur J Pharmacol. 2023 May 5;946:175579.
Hypertension pulmonaire (HTP)
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function.

Lang IM, Andreassen AK, Andersen A, Bouvaist H, Coghlan G, Escribano-Subias P, Jansa P, Kopec G, Kurzyna M, Matsubara H, Meyer BC, Palazzini M, Post MC, Pruszczyk P, Räber L, Roik M, Rosenkranz S, Wiedenroth CB, Redlin-Werle C, Brenot P.

Eur Heart J. 2023 Aug 1;44(29):2659-2671.
Hypertension pulmonaire (HTP)
Pulmonary arterial compliance and exercise capacity after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.

Sermet R, Piliero N, Guillien A, Madoun S, Doutreleau S, Salvat M, Finas M, Thony F, Vautrin E, Bouvaist H, Degano B.

ERJ Open Res. 2023 Mar 27;9(2):00590-2022.
Hypertension pulmonaire (HTP)
Diastolic ventricular function in persistent pulmonary hypertension of the newborn.

Le Duc K, Rakza T, Baudelet JB, Boukhris MR, Mur S, Houeijeh A, Storme L.

Front Pediatr. 2023 Jun 26;11:1175178.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

Long-term Outcome of Children with Newly Diagnosed Pulmonary Arterial Hypertension: Results From the Global TOPP-registry.

Changes in the management of chronic thromboembolic pulmonary hypertension over a 10-year period, in a French expert regional competence centre.

Do Low-Risk Pulmonary Arterial Hypertension Patients Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial.

Patients’ perceptions on clinical trials outcomes in pulmonary arterial hypertension therapy.

The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohort.

Hemodynamic characteristics in patients with pulmonary hypertension and chronic obstructive pulmonary disease: A retrospective monocentric cohort study.

AMPK activation by metformin protects against pulmonary hypertension in rats and relaxes isolated human pulmonary artery.

Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function.

Pulmonary arterial compliance and exercise capacity after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.

Diastolic ventricular function in persistent pulmonary hypertension of the newborn.